and less progression to AML (p = 0.033) [11] Graubert et al. (2009) MDS (20) Discovery: customized array CGH spanning chromosome 5 Validation: none (no cryptic CNAs identified) Paired normal DNA ...

Secondary-type Mutations in NPM1-mutated AML-MRC With a History of MDS or MDS/MPN Do secondary mutations explain why patients with AML with a history of myelodysplasia-related changes and the NPM1 ...

Updated results from the INWORKS study “show the importance of adherence to the basic principles of radiation protection,” according to researchers.

Using iPS cells generated from a patient with a myeloid neoplasm caused by a rare chromosomal rearrangement between the MECOM ...

Donor lymphocyte infusion, both alone and in combination with azacitidine, restored CD34 levels in two-thirds of patients ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple ...

NDAQ:RIGL) Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML ...

MDS and AML are hematopoietic diseases driven by somatically acquired genetic mutations. Cytogenetic alterations at diagnosis remain one of the most powerful prognostic factors in MDS and AML and ...

More recently, a specific type of leukemia, known as myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) with ...